April 12, 2012
Yesterday, the FDA added new adverse event language in the postmarketing experience section of the Propecia product label (see attached letter and product label revision) that warns of:
“sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders; male infertility and/or poor seminal quality (normalization or improvement of seminal quality has been reported after discontinuation of finasteride); testicular pain.”
In Questions and Answers: Finasteride Label Changes (
fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm) posted today on the FDA website,
FDA states that it “has notified healthcare professionals who would normally prescribe finasteride products—dermatologists, family practice professionals, internists and urologists—about FDA’s review of postmarketing reports and the label changes.”
FDA has required similar new warnings about persistent sexual dysfunction to be included in a parallel Proscar product label change.
THIS IS HUGE!!! Finaaaaalllly